Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14667220 | 0.84 | RIPK1 (0.61) | RIPK1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL22390532 | 0.80 | RIPK1 (0.41) | RIPK1SLC6A3SLC6A2SLC6A4KCNH2 | |
| SCHEMBL1046654 | 0.80 | MAPT (0.48) | SLC6A3SLC6A2SLC6A4DRD2GRIN2B | |
| SCHEMBL3480016 | 0.79 | RIPK1 (0.78) | RIPK1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL22389474 | 0.78 | RIPK1 (0.57) | RIPK1SLC6A2SLC6A4 | |
| SCHEMBL74595 | 0.78 | RIPK1 (0.63) | RIPK1GRIN1 | |
| SCHEMBL2091982 | 0.77 | IDO1 (0.44) | SLC6A3SLC6A2SLC6A4DRD2GRIN2B | |
| SCHEMBL2094833 | 0.77 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DRD2GRIN2B | |
| SCHEMBL17449696 | 0.77 | MGLL (0.38) | RIPK1GRIN2B | |
| SCHEMBL13875905 | 0.77 | HTT (0.51) | SLC6A3SLC6A2SLC6A4DRD2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319163-B2 | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | RIPK1 626/4885SLC6A3 4252/4885SLC6A2 4778/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | RIPK1 1775/4885SLC6A3 4468/4885SLC6A2 4710/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | RIPK1 1925/4885SLC6A3 2784/4885SLC6A2 1917/4885 |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | RIPK1 4525/4885SLC6A3 1606/4885SLC6A2 1813/4885 |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | RIPK1 1993/4885SLC6A3 4462/4885SLC6A2 3969/4885 |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | RIPK1 626/4885SLC6A3 4252/4885SLC6A2 4778/4885 |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | RIPK1 3418/4885SLC6A3 4503/4885SLC6A2 3656/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | RIPK1 486/4885SLC6A3 4294/4885SLC6A2 4355/4885 |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885SLC6A3 3925/4885SLC6A2 4695/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | RIPK1 626/4885SLC6A3 4252/4885SLC6A2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.